BioLineRx Ltd. (BLRX): Price and Financial Metrics

BioLineRx Ltd. (BLRX): $1.35

0.02 (+1.50%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add BLRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#297 of 360

in industry

BLRX Price/Volume Stats

Current price $1.35 52-week high $2.53
Prev. close $1.33 52-week low $0.55
Day low $1.32 Volume 428,706
Day high $1.43 Avg. volume 315,435
50-day MA $1.32 Dividend yield N/A
200-day MA $1.54 Market Cap 97.79M

BLRX Stock Price Chart Interactive Chart >


BioLineRx Ltd. (BLRX) Company Bio


BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company was founded in 2003 and is based in Modi’in, Israel.


BLRX Latest News Stream


Event/Time News Detail
Loading, please wait...

BLRX Latest Social Stream


Loading social stream, please wait...

View Full BLRX Social Stream

Latest BLRX News From Around the Web

Below are the latest news stories about BIOLINERX LTD that investors may wish to consider to help them evaluate BLRX as an investment opportunity.

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript November 20, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2023 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] I would […]

Yahoo | November 21, 2023

BLRX: A Series of Fortunate Events

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 3Q:23 Operational and Financial Results Activity stepped up substantially following BioLineRx Ltd.’s (NASDAQ:BLRX) report of second quarter results. Shortly after the report, the FDA approved Aphexda and BioLineRx announced the closing of the Asia deal with Gloria Biosciences. Data for the collaboration with Columbia

Yahoo | November 21, 2023

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates.

Yahoo | November 20, 2023

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open.

Yahoo | November 13, 2023

3 Tech Stocks That Wall Street Loves More Than Nvidia

Purchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market.

Michael Que on InvestorPlace | November 2, 2023

Read More 'BLRX' Stories Here

BLRX Price Returns

1-mo 18.42%
3-mo -14.56%
6-mo -44.21%
1-year 128.47%
3-year -53.29%
5-year -78.28%
YTD -14.01%
2023 166.10%
2022 -71.08%
2021 -19.05%
2020 12.00%
2019 -65.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!